Equillium (EQ) Income towards Parent Company (2018 - 2026)
Equillium's (EQ) quarterly Income towards Parent Company came in at -$15.9 million in Q1 2026, down 81.36% year-on-year from -$85.6 million in Q1 2025, and down 298.58% on a QoQ basis from -$4.0 million in Q4 2025.
Equillium (EQ) Income towards Parent Company (2018 - 2026) Analysis & Trends
Equillium (EQ) has 9 years of Income towards Parent Company data on file, last reported at -$15.9 million in Q1 2026.
- On a quarterly basis, Income towards Parent Company fell 81.36% year-over-year to -$15.9 million in Q1 2026; TTM through Mar 2026 was -$34.8 million, a 145.52% decrease from a year earlier, with the FY2025 full-year figure at -$22.4 million, down 176.31% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$15.9 million, down from -$4.0 million in the prior quarter.
- Over the last five years, Income towards Parent Company for EQ reached as high as $17.9 million in Q4 2022 and fell as low as -$37.4 million in Q1 2022.
- Historically, Income towards Parent Company has averaged -$6.7 million across 5 years, with a median of -$4.0 million in 2025.
- Across the five-year window, Income towards Parent Company surged 268.26% in 2022 and slumped 124528.57% in 2025, its largest moves.
- Year by year, Income towards Parent Company stood at $17.9 million in 2022, then plunged by 119.9% to -$3.6 million in 2023, then sank by 63.66% to -$5.8 million in 2024, then jumped by 31.41% to -$4.0 million in 2025, then slumped by 298.58% to -$15.9 million in 2026.
- Per Business Quant data, the three most recent Income towards Parent Company figures were -$15.9 million in Q1 2026, -$4.0 million in Q4 2025, and -$8.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Equillium | 242.14 Mn | 242.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.95 Mn |
| Dec 31, 2025 | -4.00 Mn |
| Sep 30, 2025 | -8.72 Mn |
| Jun 30, 2025 | -6.11 Mn |
| Mar 31, 2025 | -8.79 Mn |
| Dec 31, 2024 | -5.83 Mn |
| Sep 30, 2024 | -7,000.00 |
| Jun 30, 2024 | 468,000.00 |
| Mar 31, 2024 | -2.73 Mn |
| Dec 31, 2023 | -3.56 Mn |
| Sep 30, 2023 | -3.71 Mn |
| Jun 30, 2023 | -3.34 Mn |
| Mar 31, 2023 | -3.94 Mn |
| Dec 31, 2022 | 17.91 Mn |
| Sep 30, 2022 | -13.66 Mn |
| Jun 30, 2022 | -14.13 Mn |
| Mar 31, 2022 | -37.42 Mn |
| Dec 31, 2021 | -10.64 Mn |
| Sep 30, 2021 | -18.89 Mn |
| Jun 30, 2021 | -14.73 Mn |